Table 1.

Development status and patent expiration dates for some biosimilars of biologics used in the treatment of inflammatory diseases⁸,⁹,¹³,¹⁴,¹⁶,⁴⁰,⁴¹

Biologic	Indicationa	USA		EU
		Patent expiration	Biosimilar status	Patent expiration	Biosimilar status
Adalimumab	RA; juvenile idiopathic arthritis; psoriatic arthritis; AS; Crohn’s disease; ulcerative colitis; plaque psoriasis	2016	Phase III trials	2018	Phase III trials
Etanercept	RA; polyarticular juvenile idiopathic arthritis; psoriatic arthritis; AS; plaque psoriasis	2028	–	2015	Approved 2016
Infliximab	Crohn’s disease; pediatric Crohn’s disease; ulcerative colitis; pediatric ulcerative colitis; RA (with methotrexate); AS; psoriatic arthritis; plaque psoriasis	2018	Approved 2016	2015	Approved 2013
Rituximab	Non-Hodgkin’s lymphoma; chronic lymphocytic leukemia; RA (with methotrexate); granulomatosis with polyangiitis	2018	Phase III trials	2013	Phase III trials

Note:

^aIndications in USA.

Abbreviations: RA, rheumatoid arthritis; AS, ankylosing spondylitis.